Breaking Finance News

A statement released earlier today by RBC Capital Markets about Seattle Genetics (NDAQ:SGEN) raises the target price to $58.00

Seattle Genetics (NDAQ:SGEN) had its price target upped to $58.00 by RBC Capital Markets in an issued report issued 9/15/2017. The upped price target implies a potential upside of 0.08% based on the company's previous closing price.

Just yesterday Seattle Genetics (NDAQ:SGEN) traded 1.05% higher at $53.52. Seattle Genetics’s 50-day moving average is $49.60 and its 200-day moving average is $59.25. The last closing price is down -9.37% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.04% over the same time period. 124,489 shares of SGEN traded hands, down from an average trading volume of 1,250,890

Recent Performance Chart

Seattle Genetics (NDAQ:SGEN)

Seattle Genetics has 52 week low of $45.31 and a 52 week high of $75.36 and has a market capitalization of $0.

Brief Synopsis On Seattle Genetics (NDAQ:SGEN)

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company's pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.